The new report by Expert Market Research titled, ‘Global Haematologic Malignancies Treatment Market Growth, Share, Size, Analysis, Report and Forecast 2021-2026’, gives an in-depth analysis of the global haematologic malignancies treatment market, assessing the market based on its segments like applications, manufacturing process and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.
The key highlights of the report include:
Market Overview (2016-2026)
- Historical Market Size (2020): USD 52.1 billion
- Forecast CAGR (2021-2026): 5%
- Forecast Market Size (2026): USD 94.8billion
Globally, the rapidly growing geriatric population is expected to be a significant driver of market growth throughout the forecast period, owing to the increasing incidence of haematologic malignancies in the elderly. Advances in immunohistochemistry (IHC) have enabled the accurate diagnosis of hematologic malignancies by exposing tissue samples to a variety of antibodies directed against cell molecules and antigens. Increased investment in the discovery of physiologically effective medications, as well as a favorable reimbursement landscape, are driving market growth.
Surgical therapy can be employed to diagnose and treat lymphoma complications such as perforation, obstruction, or stricture. This, in conjunction with the release of numerous new therapies and the frequent label modifications of high-priced medications such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling market growth. Other significant market drivers include growing awareness of the possibilities of early detection of certain diseases and an increase in the number of innovative drugs approved for treatment. The market is projected to grow in the coming years owing to ongoing clinical trials aimed at developing novel treatments for patients with advanced hematologic malignancies.
Industry Definition and Major Segments
Haematologic malignancies are cancers of the blood, bone marrow, and lymph nodes. This classification includes acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukaemia (CML), myeloma, and lymphoma (Hodgkin’s and non-(NHL)). Hodgkin’s Chemotherapy, radiation, immunotherapy, and stem cell transplantation are some of the most widely recommended treatments for haematologic malignancies.
By type, the market is divided into:
- Multiple Myaeloma
By industry, the market is divided into:
- Multiple Myaeloma
By region, the industry is categorized into:
- North America
- The Asia Pacific
- Latin America
- The Middle East and Africa
Chemotherapy now accounts for a significant portion of the market for the treatment of haematologic malignancies, and it is expected to grow at a healthy rate over the forecast period. Chemotherapy is a type of cancer treatment that employs a mixture of medications to halt the growth and proliferation of cancer cells. It is used to treat a number of different types of blood malignancies. Chemotherapy decreases tumors and enables surgical resection of cancer in patients with only marginally resectable malignancies. The growing popularity of the segment is being propelled by a large patient pool and an increase in the incidence of blood cancers. Additionally, rising awareness of the risk of the condition and its subsequent treatment is expected to boost market growth.
North America is estimated to dominate the global hematologic malignancies therapy market during the forecast period. North America accounts for a substantial proportion of the market due to the presence of major players, a high prevalence of blood cancer patients, a developed healthcare infrastructure, and the availability of branded medications. Several factors are expected to drive the growth of the global market, such as advantageous government initiatives and an increase in the number of research collaborations among top market players.
Key Market Players
The major players in the market are Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Johnson & Johnson, and Takeda Pharmaceutical Co. Ltd, among Others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:
Expert Market Research (EMR) is a leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: James Rowan, Business Consultant
Email: [email protected]
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA